FindTrial
Sign In

Comparison of Ormeloxifene and Medroxyprogesterone in Treating Abnormal Uterine Bleeding

Efficacy of Ormeloxifene Versus Medroxyprogesterone Acetate in Treatment of Women with Abnormal Uterine Bleeding - A Randomised Controlled Trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/108674
Enrollment
100
Registered
2026-04-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N939- Abnormal uterine and vaginal bleeding, unspecified Health Condition 2: N939- Abnormal uterine and vaginal bleeding, unspecified

Interventions

Intervention1: nil: nil Control Intervention1: nil: nil

Sponsors

Dr Baba Saheb Ambedkar Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women aged 40 to 55 years presenting with AUB O ovulatory dysfunction E endometrial N not yet classified as per PALM COEIN Classification willing to take medical therapy

Exclusion criteria

Exclusion criteria: Active Uterine Pathology P polyp Aadenomyosis L leiomyoma M malignancy and endometrial hyperplasia C coagulopathy I iatrogenic PCOD Patients with severe medical conditions cardiovascular hepatic renal diseases thromboembolic events Hypersensitivity to these medical agents or cancer

Design outcomes

Primary

MeasureTime frame
Comparison of reduction of menstrual blood loss PBAC and haemoglobin level in both groups Comparison of change in endometrial thickness in both groupsTimepoint: 3rd month 6th month—

Secondary

MeasureTime frame
Side effects of Ormeloxifene & Medroxyprogesterone Acetate in respective groups Difference in compliance of treatment given in both groupsTimepoint: 1st visit 3rd month 6th month—

Countries

India

Contacts

Public ContactAnupa Singhal

Dr Baba Saheb Ambedkar Medical College and Hospital

anupasinghal@gmail.com9810558744

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026